Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
CardiovascularINTRAMUSCULARGeneric

PRIMAXIN

CILASTATIN SODIUM; IMIPENEM

Standard Dose
EQ 500MG BASE/VIAL;500MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: UNKNOWN Marketing status: Discontinued
Summary

Approval overview PRIMAXIN is listed in Drugs@FDA under application 050630 (NDA).

Review priority: UNKNOWN Marketing status: Discontinued Active ingredient CILASTATIN SODIUM; IMIPENEM Form and strength POWDER;INTRAMUSCULAR - EQ 500MG BASE/VIAL;500MG/VIAL Sponsor MERCK Submission history Latest submission status date: 2009-08-26 00:00:00.

Structured Monograph

Clinical summary

Approval overview PRIMAXIN is listed in Drugs@FDA under application 050630 (NDA). Review priority: UNKNOWN Marketing status: Discontinued Active ingredient CILASTATIN SODIUM; IMIPENEM Form and strength POWDER;INTRAMUSCULAR - EQ 500MG BASE/VIAL;500MG/VIAL Sponsor MERCK Submission history Latest submission status date: 2009-08-26 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: UNKNOWN

Interaction Notes

  • No interaction notes stored yet.
PRIMAXIN (CILASTATIN SODIUM; IMIPENEM) | Drug Monograph | MedicHelpline